Advertisement
Singapore markets open in 28 minutes

  • Straits Times Index

    3,313.48
    +8.49 (+0.26%)
     

  • S&P 500

    5,303.27
    +6.17 (+0.12%)
     

  • Dow

    40,003.59
    +134.19 (+0.34%)
     

  • Nasdaq

    16,685.97
    -12.33 (-0.07%)
     

  • Bitcoin USD

    66,204.24
    -738.57 (-1.10%)
     

  • CMC Crypto 200

    1,351.99
    -21.85 (-1.59%)
     

  • FTSE 100

    8,420.26
    -18.39 (-0.22%)
     

  • Gold

    2,424.30
    +6.90 (+0.29%)
     

  • Crude Oil

    79.81
    -0.25 (-0.31%)
     

  • 10-Yr Bond

    4.4200
    +0.0430 (+0.98%)
     

  • Nikkei

    38,849.92
    +62.54 (+0.16%)
     

  • Hang Seng

    19,553.61
    +177.11 (+0.91%)
     

  • FTSE Bursa Malaysia

    1,616.62
    +5.51 (+0.34%)
     

  • Jakarta Composite Index

    7,317.24
    -7,246.70 (-49.76%)
     

  • PSE Index

    6,618.69
    -9.51 (-0.14%)
     

Vertex (VRTX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

Zacks Equity Research
·2-min read

For the quarter ended March 2024, Vertex Pharmaceuticals (VRTX) reported revenue of $2.69 billion, up 13.3% over the same period last year. EPS came in at $4.76, compared to $3.05 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $2.56 billion, representing a surprise of +5.15%. The company delivered an EPS surprise of +16.10%, with the consensus EPS estimate being $4.10.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

ADVERTISEMENT

Here is how Vertex performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Geographic Revenues- United States: $1.52 billion versus $1.56 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +8.3% change.

  • Geographic Revenues- Outside of the United States: $1.17 billion compared to the $997.71 million average estimate based on three analysts.

  • Revenues by Product- Trikafta/Kaftrio: $2.48 billion compared to the $2.41 billion average estimate based on eight analysts. The reported number represents a change of +18.5% year over year.

View all Key Company Metrics for Vertex here>>>

Shares of Vertex have returned +1.4% over the past month versus the Zacks S&P 500 composite's -0.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Vertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research